Table 1.
Basic characteristics of study population for the value of serum pyruvate kinase Isoenzyme M2 and carcinoembryonic antigen in colorectal cancer mass screening in Hangzhou, China, 2006-2008 (mean ± SD)
| Colorectal lesion | n |
Gender |
Age (yr) | M2-PK (U/mL) | CEA (ng/mL) | |
| Male | Female | |||||
| Colorectal cancer | ||||||
| Stage I and II | 55 | 53 | 40 | 59.17 ± 10.71 | 13.10 ± 12.07 | 5.74 ± 7.49 |
| Stage III | 38 | 14.75 ± 13.39 | 5.68 ± 5.43 | |||
| Advanced adenoma | 41 | 25 | 16 | 60.17 ± 7.78 | 8.58 ± 7.65 | 2.68 ± 1.43 |
| Adenoma | 137 | 68 | 69 | 60.34 ± 8.16 | 6.70 ± 6.97 | 2.58 ± 3.74 |
| Nonadenomatous polyp | 47 | 25 | 22 | 59.04 ± 8.08 | 5.13 ± 3.73 | 2.55 ± 2.09 |
| IBD | 7 | 1 | 6 | 57.43 ± 7.16 | 2.51 ± 1.94 | 1.71 ± 0.91 |
| Normal | 158 | 56 | 102 | 57.15 ± 7.96 | 2.96 ± 2.17 | 1.98 ± 1.02 |
IBD: Inflammatory bowel disease; M2-PK: M2-pyruvate kinase; CEA: Carcinoembryonic antigen.